Global Tamiflu (Oseltamivir Phosphate) Drugs Market, By Drug Class (Neuraminidase Inhibitors, Others), Type (Branded, Generic), Patient Demographic (Adults, Geriatric, Pediatric), Indication (Influenza A, Influenza B, Others), Dosage Form (Capsule, Suspension), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2029
Market Analysis and Size
The tamiflu (oseltamivir phosphate) market is changing as healthcare organizations, particularly in the United States, are increasingly shifting to OTC distribution. As the United States is one of North America's fastest-growing economies, it is anticipated to have the second-highest revenue in the tamiflu (oseltamivir phosphate) market by 2027. As a result, corporations in the United States are cashing in on the OTC switch trend. According to prominent market players, even emerging market companies are striving for the OTC switch and strategic transactions to introduce tamiflu (oseltamivir phosphate) advancements.
Data Bridge Market Research analyses that the tamiflu (oseltamivir phosphate) drugs market was valued at USD 542.88 billion in 2021 and is expected to reach USD 862.85 billion by 2029, registering a CAGR of 5.40% during the forecast period of 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Drug Class (Neuraminidase Inhibitors, Others), Type (Branded, Generic), Patient Demographic (Adults, Geriatric, Pediatric), Indication (Influenza A, Influenza B, Others), Dosage Form (Capsule, Suspension), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.), Novartis AG (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd.(Israel), Sanofi (France), F. Hoffmann-La Roche Ltd. (Switzerland), Lupin (India), Amneal Pharmaceuticals LLC. (U.S.), Cipla Inc. (U.S.), NATCO Pharma Limited (India), Macleods Pharmaceuticals Ltd (India), Strides Pharma Science Limited (India), Alembic Pharmaceuticals Limited (India), Hetero (India), Alvogen (U.S.), Sun Pharmaceutical Industries Ltd. (India), Zydus Cadila (India), Lotus International (U.S.)
|
|
Market Opportunities
|
|
Market Definition
Tamiflu is an antiviral medicine that can be used to treat influenza. Tamiflu is an antiviral drug that works by suppressing the neuraminidase enzyme in the body, which aids in viral reproduction. This medicine stops new viruses from infecting host cells and activates enzymes (neuraminidases) found inside live organisms' cell membranes responsible for releasing offspring viruses after an infection with any organism. Furthermore, regular tamiflu treatment minimizes the severity of flu-related complications such as nausea, vomiting, and diarrhoea, lowering the risk of hospitalization due to viral fever or other influenza-related symptoms.
Tamiflu (Oseltamivir Phosphate) Drugs Market Dynamics
Drivers
- Rise in the prevalence of influenza diseases
The surging prevalence of influenza diseases is a major factor driving the tamiflu (oseltamivir phosphate) drugs market's growth rate during the forecast period of 2022-2029. According to the Centers for Disease Control and Prevention (CDC), the flu affects between 5% and 20% of the population in the United States each year. In addition, 200,000 individuals are hospitalized in the United States each year due to flu infection, with 36,000 of them dying from flu complications. Tamiflu is used to treat acute and uncomplicated influenza A and B in patients aged 2 weeks and older who have been symptomatic for less than 48 hours. It is also prescribed for the prevention of influenza A and B in patients aged one year and up.
- Increasing investment for healthcare infrastructure
Another significant factor influencing the growth rate of tamiflu (oseltamivir phosphate) drugs market is the rising healthcare expenditure which helps in improving its infrastructure. Following COVID-19, people's attitudes around health have shifted significantly. People's attitudes are evolving from disease treatment to disease prevention, and their total awareness of such drugs is increasing day by day. Governments around the world are investing more funding to improve and develop new healthcare infrastructure. Healthcare spending in the United States is expected to surpass 20% of GDP by 2028. All of these factors are estimated to drive the tamiflu (oseltamivir phosphate) drugs market forward.
Furthermore, rising initiatives by public and private organizations to spread awareness and rising healthcare expenditure will expand the tamiflu (oseltamivir phosphate) drugs market. Additionally, sedentary lifestyle of people and surging geriatric population will result in the expansion of tamiflu (oseltamivir phosphate) drugs market.
Opportunities
- Increase in the number of research and development activities
The rising research and development activities are estimated to create new opportunities for the tamiflu (oseltamivir phosphate) drugs market growth in coming years.
Moreover, rising investment for the development of advanced technologies and increase in the number of emerging markets will further provide beneficial opportunities for the tamiflu (oseltamivir phosphate) drugs market growth during the forecast period.
Restraints/Challenges
- Side effects associated with tamiflu (oseltamivir phosphate) drugs
Side effects associated with tamiflu (oseltamivir phosphate) drugs will obstruct the growth rate of market. Severe side effects from oseltamivir include nausea, gastroenteritis, and stomach discomfort. It can lead to life-threatening health consequences in some situations, including heart attack, severe liver disease, and kidney problems. These limitations have the potential to stifle overall market growth.
On the other hand, the lack of healthcare infrastructure in developing economies and dearth of skilled professionals will challenge the tamiflu (oseltamivir phosphate) drugs market. Additionally, strict government regulations and the high cost of tamiflu (oseltamivir phosphate) drugs will restrain and further impede the growth rate of market during the forecast period of 2022-2029.
This tamiflu (oseltamivir phosphate) drugs market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the tamiflu (oseltamivir phosphate) drugs market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Patient Epidemiology Analysis
Tamiflu (oseltamivir phosphate) drugs market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
COVID-19 Impact on Tamiflu (Oseltamivir Phosphate) Drugs Market
The COVID-19 outbreak and subsequent lockdown in numerous countries around the world had a huge impact on the financial status of enterprises in all sectors. The private healthcare sector is one of the areas where the pandemic had a significant impact.
The outbreak of the COVID-19 virus has boosted the market for tamiflu (oseltamivir phosphate) drugs. A global pandemic has resulted from the rapid spread of the severe acute respiratory sickness COVID-19 in the human immunology population. COVID-19 particles may survive for several days on surfaces, although being enveloped viruses, they are susceptible to desiccation and mild detergent disinfection. Because nasal secretions contain the spreadable virus, disease progression and contagiousness appear to peak before or immediately after symptom onset. COVID-19 oral medication might be easily manufactured, transported, and stored, making it more convenient to obtain and use. Antivirals, such Tamiflu, are best taken as soon as possible to reduce the risk of serious illness. Tamiflu's strategy to treat COVID-19 has several advantages over current medications that require intravenous infusions, including monoclonal antibodies and convalescent plasma.
Global Tamiflu (Oseltamivir Phosphate) Drugs Market Scope
The tamiflu (oseltamivir phosphate) drugs market is segmented on the basis of indication, dosage form, drug class, type, patient demographic, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Drug Class
- Neuraminidase Inhibitors
- Others
Type
- Branded
- Generic
Patient Demographic
- Adults
- Geriatric
- Pediatric
Dosage Form
- Capsule
- Suspension
Indication
- Influenza A
- Influenza B
- Others
Route of Administration
- Oral
- Parenteral
- Others
End-Users
- Hospitals
- Specialty Clinics
- Homecare
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
Tamiflu (Oseltamivir Phosphate) Drugs Market Regional Analysis/Insights
The tamiflu (oseltamivir phosphate) drugs market is analysed and market size insights and trends are provided by country, indication, dosage form, drug class, type, patient demographic, route of administration, end-users and distribution channel as referenced above.
The countries covered in the tamiflu (oseltamivir phosphate) drugs market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
North America dominates the tamiflu (oseltamivir phosphate) drugs market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period,due to the presence of major key players and rising healthcare expenditure will further propel the market’s growth rate in this region. Additionally, an increase in the number of FDA-approved drugs and high prevalence of influenzas illness will further propel the market’s growth rate in this region.
Asia-Pacific is expected to grow during the forecast period of 2022-2029 due to surging level of disposable income in this region. Also, development of healthcare infrastructure and rise in number of generic manufacturers will further propel the market’s growth rate in this region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Tamiflu (Oseltamivir Phosphate) Drugs Market Share Analysis
The tamiflu (oseltamivir phosphate) drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to tamiflu (oseltamivir phosphate) drugs market.
Some of the major players operating in the tamiflu (oseltamivir phosphate) drugs market are:
- Pfizer Inc. (U.S.)
- GlaxoSmithKline plc (U.K.)
- Novartis AG (Switzerland)
- Mylan N.V. (U.S.)
- Teva Pharmaceutical Industries Ltd.(Israel)
- Sanofi (France)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Zydus Cadila (India)
- Lupin (India)
- Amneal Pharmaceuticals LLC. (U.S.)
- Cipla Inc. (U.S.)
- NATCO Pharma Limited (India)
- Macleods Pharmaceuticals Ltd (India)
- Strides Pharma Science Limited (India)
- Alembic Pharmaceuticals Limited (India)
- Hetero (India)
- Alvogen (U.S.)
- Sun Pharmaceutical Industries Ltd. (India)
- Zydus Cadila (India)
- Lotus International (U.S.)
SKU-